Dipeptidyl peptidase-4 inhibitors along with chance of venous thromboembolism: information prospecting regarding FDA negative occasion canceling technique.
Dipeptidyl peptidase-4 inhibitors along with chance of venous thromboembolism: information prospecting regarding FDA negative occasion canceling technique.